Current position

Ray Dalio’s Boston Scientific Corp (BSX) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Bridgewater Associates, LPVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ3 2006Earliest verified positive filing snapshot
Latest statusCurrent positionBased on the latest supported relationship state
Peak shares2.65MHighest verified quarter-end share count
Quarters reported49Verified quarters with shares above zero
What happened?

Bridgewater Associates, LP first reported Boston Scientific Corp in Q3 2006. After an earlier exit, the position later appeared again in a verified filing. The reported position was increased and reduced across later filings. Bridgewater Associates, LP currently reports 442.04K shares. The latest verified filing showed: Bought 474.1% more.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2026
Bought 474.1% more+365.04K shares · 442.04K shares reported after the change
Filing context

Quarter-end price $42.68 · Estimated holding basis $49.28

Q1 2026
Sold 17.9% of the position−16.75K shares · 76.99K shares remained
Filing context

Quarter-end price $62.75 · Estimated holding basis $80.58

Q4 2025
Sold 41.3% of the position−65.98K shares · 93.75K shares remained
Filing context

Quarter-end price $95.35 · Estimated holding basis $80.58

Q3 2025
Bought 230.8% more+111.45K shares · 159.73K shares reported after the change
Filing context

Quarter-end price $97.63 · Estimated holding basis $80.58

Q2 2025
Sold 24.5% of the position−15.67K shares · 48.28K shares remained
Filing context

Quarter-end price $107.41 · Estimated holding basis $41.22

Q1 2025
Sold 60.7% of the position−98.96K shares · 63.95K shares remained
Filing context

Quarter-end price $100.88 · Estimated holding basis $41.22

Portfolio importance

How important is Boston Scientific Corp in Bridgewater Associates, LP’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Current portfolio weight0.1%Q2 2026
Current rank#218of 997 reported positions
Peak portfolio weight0.6%Q1 2023
Best historical rank#33Q2 2023
At peak importanceQ1 2023
BSX
0.6%
Largest holding
5.3%
Cross-investor discovery

Who else owns Boston Scientific Corp?

Also reported by 1 other tracked investor in their latest verified filings.

Joel GreenblattGotham Asset Management
BSX0.0% of reported portfolio
Explore Boston Scientific Corp across all tracked investors →
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$45.052026-09-14

Market context only; not an investor transaction price.

Latest filing quarter-end price$42.68Q2 2026

Derived from validated reported value and shares where supported.

Estimated holding basis$49.28Historical reference — not actual purchase price

Calculated from supported filing history.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

This tracker follows Bridgewater Associates, LP’s Form 13F disclosures, not Ray Dalio’s personal brokerage account. Form 13F reports quarter-end positions later and does not reveal exact trade dates or execution prices.